Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ: CRSP )

40.30 +1.26 (+3.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Via The Motley Fool
My 10 Top Stocks to Buy to Start the New Year Off Right
Via The Motley Fool
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
Via The Motley Fool
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
1 big new Green Flag for CRISPR Therapeutics' Stock
Via The Motley Fool
Where Will CRISPR Therapeutics Be in 3 Years?
Via The Motley Fool
3 Mid-Cap Stocks That Could Take Off in 2025
Via The Motley Fool
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
Exposures Product Safety
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
Via The Motley Fool
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Via The Motley Fool
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
Via The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in December
Via The Motley Fool
3 of the Best Growth Stocks You Can Buy for Less than $100
Via The Motley Fool
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%
Via The Motley Fool
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13. 
Via Benzinga
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
Deciphering Disruption: Inside Cathie Wood's Latest Plays
Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies. 
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Via The Motley Fool
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029
These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The rock star fund investor made a lot of big moves on Thursday. 
Via The Motley Fool
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
3 Companies Building Tomorrow's Game-Changing Technologies
These pioneering companies are transforming delivery, medicine, and space access--potentially creating massive opportunities for early investors. 
Via The Motley Fool
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
It won't be able to be profitable without hitting its targets for both of these figures. 
Via The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
The Ultimate Biotech Stock to Buy With $50 Right Now
This company might be worth far more than many realize. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.